|
Association of KRT20 and KRT5 with response to neoadjuvant chemotherapy in patients diagnosed with muscle invasive bladder cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Leadership - STRATIFYER Molecular Pathology |
Research Funding - Janssen |
|
|
No Relationships to Disclose |
|
|
Research Funding - Janssen |
|
|
No Relationships to Disclose |
|
|
Research Funding - Janssen-Cilag (Inst) |
|
|
Honoraria - Astellas Oncology; AstraZeneca; Diaceutics; Janssen-Cilag; MSD; Roche |
Consulting or Advisory Role - AstraZeneca; Diaceutics; Genomic Health; Janssen-Cilag |
Research Funding - Janssen-Cilag; Roche; STRATIFYER Molecular Pathology |
|
|
|
Consulting or Advisory Role - Ipsen |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; AstraZeneca; Janssen-Cilag; Medac; Takeda |
Research Funding - ERBE Elektromedizin (Inst) |
|
|
Honoraria - Amgen; Falk Pharma; Medupdate; Merck; Pathohistological Testimonials for insurances; Pfizer |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Merck Sharp & Dohme; Roche Pharma AG |
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen |